Vigil Neuroscience
VIGL
VIGL was delisted on the 4th of August, 2025.
58 hedge funds and large institutions have $105M invested in Vigil Neuroscience in 2024 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 13 increasing their positions, 17 reducing their positions, and 16 closing their positions.
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
15% more capital invested
Capital invested by funds: $90.5M → $105M (+$14M)
7% more funds holding
Funds holding: 54 → 58 (+4)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2.35% less ownership
Funds ownership: 71.89% → 69.54% (-2.3%)
24% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.08M |
| 2 |
SC
Stempoint Capital
New York
|
+$2.55M |
| 3 |
Goldman Sachs
New York
|
+$1.31M |
| 4 |
Millennium Management
New York
|
+$1.03M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$707K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$3.41M |
| 2 |
DM
Deerfield Management
New York
|
-$3.34M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.47M |
| 4 |
BlackRock
New York
|
-$1.62M |
| 5 |
State Street
Boston,
Massachusetts
|
-$840K |
VIGL Hedge Fund Activity: Q2 2024 in Review
58 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Vigil Neuroscience (VIGL) for Q2 2024, worth a combined $105M — up 15% from $90.5M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new VIGL positions and 16 closed out — a net gain of 4 holders — while 13 added to existing stakes and 17 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $5.08M. The largest seller was Deep Track Capital, cutting an estimated $3.41M.
- 58 institutional investors held Vigil Neuroscience (VIGL) as of Q2 2024, up from 54 in Q1 2024.
- Funds reported $105M of Vigil Neuroscience stock for Q2 2024, up 15% quarter-over-quarter.
- 20 funds opened new Vigil Neuroscience positions in Q2 2024 and 16 closed out, a net change of +4 holders.
- The largest Vigil Neuroscience buyer in Q2 2024 was Point72 Asset Management, an estimated $5.08M added.
- The largest Vigil Neuroscience seller in Q2 2024 was Deep Track Capital, an estimated $3.41M sold.
Based on aggregated 13F filings for Q2 2024.